ARVN NASDAQ
Arvinas, Inc.
1W: -3.4%
1M: -14.4%
3M: -24.1%
YTD: -20.7%
1Y: +37.0%
3Y: -61.0%
5Y: -86.4%
$9.09
-0.01 (-0.11%)
Weekly Expected Move ±6.0%
$8
$9
$9
$10
$10
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (44)
Arvinas Employees Give Back During Company-wide Impact Day
These Analysts Increase Their Forecasts On Arvinas After Q1 Results
Rigel Pharmaceuticals Inks Breast Cancer Drug Deal With Arvinas, Pfizer
Arvinas, Inc. (ARVN) Reports Q1 Loss, Misses Revenue Estimates
Pfizer, Arvinas ink licensing deal with Rigel for breast cancer therapy
Earnings Scheduled For May 12, 2026
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue Estimates
Arvinas Q1 2026 Earnings Preview
Codexis (CDXS) Reports Q1 Loss, Beats Revenue Estimates
Earnings Preview: ProQR (PRQR) Q1 Earnings Expected to Decline
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Arvinas to Report First Quarter 2026 Financial Results on May 12, 2026
Pfizer, Arvinas Win FDA Nod For First-Of-Its-Kind Breast Cancer Therapy
Pfizer, Arvinas breast cancer therapy approved by the FDA
Arvinas Announces FDA Approval of VEPPANU (vepdegestrant) for the Treatment of ESR1m, ER+/HER2- Advanced Breast Cancer
JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN
JPMorgan Chase & Co. Has $1.83 Million Stock Holdings in Arvinas, Inc. $ARVN
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas (ARVN) Moves 6.9% Higher: Will This Strength Last?
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Rating of “Hold” from Analysts
Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson's Disease Treated for 28 Days
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders
Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders
Arbiter Partners Capital Management LLC Invests $3.86 Million in Arvinas, Inc. $ARVN
Arvinas outlines 2026 clinical data milestones and maintains cash runway into second half of 2028 amid strategic pipeline focus
Arvinas, Inc. (ARVN) Q4 2025 Earnings Call Transcript
Arvinas GAAP EPS of -$1.10 misses by $0.62, revenue of $9.5M misses by $27.76M
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Here are the major earnings before the open Tuesday
Arvinas Q4 2025 Earnings Preview
Arvinas to Participate in Upcoming Investor Conferences
Arvinas to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Arvinas, Inc. (NASDAQ:ARVN) Sees Large Drop in Short Interest
Arvinas Announces Appointment of Randy Teel, Ph.D., as President, Chief Executive Officer, and Director
Arvinas, Inc. (NASDAQ:ARVN) Receives Consensus Recommendation of “Hold” from Brokerages
Arvinas (NASDAQ:ARVN) Shares Down 2.6% – Should You Sell?
Caxton Associates LLP Takes $2.19 Million Position in Arvinas, Inc. $ARVN
Arvinas, Inc. (NASDAQ:ARVN) Receives Average Recommendation of “Hold” from Analysts
Arvinas Presents Preclinical Data Supporting Mechanistic Synergies and Enhanced Antitumor Activity with the Combination of ARV-393 and Glofitamab at the 2025 American Society of Hematology Annual Meeting and Exposition
Arvinas to Present at Piper Sandler 37th Annual Healthcare Conference
Arvinas Announces Data Presentations from the Vepdegestrant (ARV-471) Clinical Development Program at the 2025 San Antonio Breast Cancer Symposium (SABCS)